Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News

THE WOODLANDS, Texas--(BUSINESS WIRE)--

Opexa Therapeutics, Inc. (OPXA), a biotechnology company developing Tcelna, a novel T-cell immunotherapy for the treatment of multiple sclerosis (MS), today announced that Opexa will be highlighted in an upcoming broadcast of "The RedChip Money Report: Small Stocks Big Money," a nationally televised financial program. The broadcast will include an interview with Opexa's President and Chief Executive Officer, Neil K. Warma, and is scheduled to air on Thursday, October 17th at 10:00 p.m. PDT on the Fox Business Network.

The interview will include a corporate update and financial highlights, as well as provide an overview of Opexa's ongoing Phase IIb clinical trial for Secondary Progressive MS, the Abili-T trial, being conducted in the United States and Canada.

The "RedChip Money Report" segment from Fox Business will be made available on the investor relations page of Opexa's website.

"The RedChip Money Report: Small Stocks Big Money" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and president of RedChip, an international small-cap research firm and an Inc. 5000 company. Mr. Gentry has made multiple guest appearances on both CNBC and Fox Business News and has been a consultant to hundreds of public companies.

About Opexa

Opexas mission is to lead the field of Precision Immunotherapy by aligning the interests of patients, employees and shareholders. The Companys leading therapy candidate, Tcelna, is a personalized T-cell immunotherapy that is in a Phase IIb clinical development program (the Abili-T trial) for the treatment of Secondary Progressive MS. Tcelna is derived from T-cells isolated from the patients peripheral blood, expanded ex vivo, and reintroduced into the patients via subcutaneous injections. This process triggers a potent immune response against specific subsets of autoreactive T-cells known to attack myelin.

About Multiple Sclerosis (MS)

MS is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately two million people have MS worldwide.

While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common. The Secondary Progressive form of MS represents about a third of the MS patient population.

See original here:
Opexa Therapeutics CEO to Appear on The RedChip Money Report on Fox Business News